If you're looking for ASX tech shares to buy, then it could be worth checking out Chrysos Corporation Ltd (ASX: C79).
In case you're not familiar with Chrysos, it provides technology solutions to the global mining industry.
Its flagship product is PhotonAssay, which was developed at Australia's national science agency, CSIRO.
PhotonAssay delivers faster, safer, more accurate, and environmentally-friendly analysis of gold, silver, copper and other elements. The company notes that the technology has rapidly displaced slower, more hazardous and costly processes to become the mining industry's most innovative and valuable assaying solution.
Last month, the company revealed that its growing popularity with end users helped underpin a sizeable 62% increase in revenue to $19.8 million during the first half of FY 2024.
Image source: Getty Images
Why is Chrysos an ASX tech share to buy?
Bell Potter notes that UK-based mining services provider Capital has just released its results and outlook for 2024.
Its subsidiary MSALABS has the largest international network of Chrysos PhotonAssay technology.
According to the note, deployments into MSALABS's network is on track and the company has reiterated its multi-year expansion strategy, which emphasises PhotonAssay deployments.
Bell Potter highlights that Capital advised that "MSALABS relationship with Chrysos remains strong and will see the deployment of 21 units" in 2024. This compares to its previous guidance for these 21 deployments to be made by 2025.
It sees this as a big positive and appears to believe it supports its view that PhotonAssay is on its way to winning a significant market share. It commented:
We believe C79's disruptive PhotonAssay technology will command a significant foothold within the large gold assaying market (BPe 25% market penetration by FY30), with current lease agreements providing good near-term deployment visibility. These lease agreements with some of the largest gold miners and international laboratory businesses provide third-party technical and commercial validation for PhotonAssay technology adoption, which should support further industry take-up.
Big returns could be coming
The note reveals that Bell Potter has reaffirmed its buy rating on the ASX tech share with a price target of $8.30.
Based on its current share price of $6.55, this implies potential upside of approximately 27% for investors over the next 12 months.
